Serious adverse events (SAEs) related to the drug occurred in 2 patients (10%), including 1 case of Grade 4 neutropenia (20%) and 1 case of Grade 2–3 elevated ALT and AST (20%). This evidence concerns the gene GPT and Decreased total neutrophil count.